Albany, NY -- (SBWIRE) -- 03/27/2019 -- Cutaneous T-cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast 2027- Market Insights, Epidemiology and Market Forecast-2027

25 March 2019

Men account for over 53% of total cases of CTCL as compared to women.
- Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma.
- More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body.
- There are different subtypes of CTCL. Most are slow growing but some can be fast growing. The most common types of CTCL are Mycosis Fungoides and Sezary Syndrome.

(Albany, US) DelveInsight launched a new report on Cutaneous T-cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2027

Key Benefits

- Cutaneous T-cell lymphoma report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T-cell lymphoma (CTCL) market.
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell lymphoma (CTCL) market.
- To understand the future market competition in the Cutaneous T-cell lymphoma (CTCL) market.
Request for sample pages

"Cutaneous T-cell Lymphoma market size was about USD 698.47 Billion in 2016 in the 7MM and growing at an increasing CAGR during the forecasted period (2018-2027)."

As per DelveInsight estimates, men account for over 53% of total cases of CTCL, as compared to women. The total incident population of CTCL in the 7 major markets was approximately 8400 cases in 2016. DelveInsight estimates higher incident cases of CTCL in the United States with approximately 3,200 incident cases in 2016, followed by EU5 and Japan and also, there are approximately 1,700 cases of Mycosis fungoides in 2016 in the US. The incidence rate of Mycosis fungoides has been increasing significantly since the 1970s.

The Cutaneous T-cell Lymphoma treatment depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The highest Cutaneous T-cell Lymphoma (CTCL) market share was of the United States, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan in 2016. The market size for the Early Stage First Line & Second Line Therapies of CTCL in the United States was found to be approximately USD 28.22 Million and USD 265.3 Million respectively in 2016.

Cutaneous T-cell Lymphoma Drug Companies
1. Celgene Corporation
2. Kyowa Hakko Kirin Co, Ltd
3. Actelion
4. Mallinckrodt Pharmaceuticals
5. Eisai Co., Ltd
and many others.

Drugs that are involved are
1. Istodax (Romidepsin)
2. Potelegio (Mogamulizumab)
3. Valchlor/ Ledaga (Mechlorethamine)
4. Uvadex (Methoxsalen)
5. Targretin (Bexarotene)
And many others

Table of contents

1. Key Insights
2. Cutaneous T- Cell Lymphoma (CTCL) Market Overview at a Glance
3. Cutaneous T- Cell Lymphoma (CTCL) Disease Background and Overview
4. Cutaneous T- Cell Lymphoma (CTCL) Epidemiology and Patient Population
5. Cutaneous T- Cell Lymphoma (CTCL) Incident Population in 7MM
6. Cutaneous T- Cell Lymphoma (CTCL) Country Wise-Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. The United Kingdom
6.8. Japan
7. Treatment Algorithm, Current Treatment, and Medical Practices
7.1. International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
7.2. United States
7.3. Europe
8. Unmet Needs
9. Cutaneous T- Cell Lymphoma (CTCL) Marketed Drugs
9.1. Istodax (Romidepsin): Celgene Corporation
9.2. Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
9.3. Valchlor/ Ledaga (Mechlorethamine): Actelion
9.5. Targretin (Bexarotene): Eisai Co., Ltd.
9.6. Zolinza (Vorinostat): Merck Sharp & Dohme Corp.
9.7. Adcetris (Brentuximab Vedotin): Seattle Genetics
10. Cutaneous T- Cell Lymphoma (CTCL) Emerging Therapies
11. Cutaneous T- Cell Lymphoma (CTCL) 7 Major Market Analysis
12. The United States Market Outlook
13. EU-5 Countries: Market Outlook
13.1. Germany
13.2. France
13.3. Italy
13.4. Spain
13.5. United Kingdom
13.6. Japan: Market Outlook
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight